BioStock: WntResearch continues towards phase II results
For WntResearch, 2020 has been characterised by work on the phase II study with the company’s main candidate Foxy-5, developed to prevent cancer metastases. Another important event was the oversubscribed share issue that was carried out during the spring. BioStock talked to CEO Peter Morsing to hear more about the past six months and what the rest of 2020 has to offer WntResearch.
Read the full interview at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se